论文部分内容阅读
据研究人员报道,标准剂量的减体(debulking)化疗后顺序附加给予高剂量的化疗药物美罗华(rituximab),则有可能提高套细胞淋巴瘤患者的长期无瘤生存率和总体生存率。来自于意大利血液学部门的9位研究人员对28例患有晚期套细胞淋巴瘤且预先未经治疗的患者进行了研究。患者在接受了3
According to the researchers, sequential addition of high doses of rituximab to standard doses of debulking chemotherapy may increase the long-term, tumor-free survival and overall survival of patients with mantle cell lymphoma. Nine researchers from the Italian Department of Hematology conducted a study of 28 patients with advanced mantle cell lymphoma who were previously untreated. Patient was accepted 3